Biocompare.com RSS feed http://www.biocompare.com/ © 2010 Biocompare.com Sun, 01 Aug 2010 02:48:49 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ Abbott (NYSE:ABT - News) today received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin - the most commonly prescribed dose of simvastatin - with either 500 mg or 1,000 mg of niacin extended-release. SIMCOR is the first treatment to combine Abbott's proprietary niacin extended-release and simvastatin, the most commonly used statin. http://news.biocompare.com/newsstory.asp?id=335996 Biocompare.com Fri, 30 Jul 2010 15:21:00 GMT U.S. health officials warned Thursday about the risk of pneumonia with Cubist Pharmaceuticals Inc's (CBST.O) flagship antibiotic. http://news.biocompare.com/newsstory.asp?id=335995 Biocompare.com Fri, 30 Jul 2010 15:19:00 GMT A decision by a U.S. appeals court could pave the way for cheaper generic forms of Eli Lilly and Co's Gemzar cancer drug to be launched in the United States beginning in mid-November. http://news.biocompare.com/newsstory.asp?id=335989 Biocompare.com Fri, 30 Jul 2010 15:12:00 GMT WALTHAM, Mass., July 29 /PRNewswire/ --Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in 2014, sales of drugs from multinational corporations will represent 92 percent of Mexico's non-small-cell lung cancer drug market. Factors promoting the market's growth include a modest increase in the use of premium-priced chemotherapies and targeted agents, brand loyalty among prescribing oncologists and an increase in diagnosed incident cases. http://news.biocompare.com/newsstory.asp?id=335849 Biocompare.com Fri, 30 Jul 2010 04:07:00 GMT Optimer Pharmaceuticals, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) for fidaxomicin to the European Medicines Agency (EMA) under the European Union's Centralized Procedure. Optimer is seeking approval to market fidaxomicin for the treatment of patients with Clostridium difficile infection (CDI). http://news.biocompare.com/newsstory.asp?id=335821 Biocompare.com Fri, 30 Jul 2010 04:06:00 GMT Danbury, CT. ? July 28, 2010 ? ATMI, Inc. (NASDAQ: ATMI) announced yesterday the completion of a two-year, multi-million dollar expansion project for its Bloomington, Minnesota manufacturing facility. With this achievement, the company establishes its North American hub for the production, marketing and development of its IntegrityTM single-use technologies for biopharmaceutical and other life science applications. http://news.biocompare.com/newsstory.asp?id=335737 Biocompare.com Thu, 29 Jul 2010 07:59:00 GMT Abbott today received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin - the most commonly prescribed dose of simvastatin - with either 500 mg or 1,000 mg of niacin extended-release. SIMCOR is the first treatment to combine Abbott's proprietary niacin extended-release and simvastatin, the most commonly used statin. http://news.biocompare.com/newsstory.asp?id=335705 Biocompare.com Thu, 29 Jul 2010 05:34:00 GMT Advanced Life Sciences Holdings, Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for Fast-Track designation for Restanza?, a novel once-daily oral antibiotic, for the treatment of community acquired bacterial pneumonia (CABP). http://news.biocompare.com/newsstory.asp?id=335598 Biocompare.com Thu, 29 Jul 2010 05:33:00 GMT ACCESS PHARMACEUTICALS, INC.,a biopharmaceutical company specializing in products for cancer and supportive care, announced today that Zacks Investment Research has issued a research update summarizing some of the recent positive developments that the Company has been able to achieve which have led to reiteration of the 'Outperform' rating on ACCP and a six-twelve month price target of $8.00. http://news.biocompare.com/newsstory.asp?id=335619 Biocompare.com Thu, 29 Jul 2010 05:33:00 GMT Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the rheumatoid arthritis (RA) drug market, the uptake of alternative biologics such as Roche/Chugai's Actemra/RoActemra will erode the market share of TNF-alpha inhibitors over the next decade. Actemra/RoActemra will emerge as the likely preferred biologic agent for TNF-refractory patients and will garner blockbuster sales of approximately $1.5 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. http://news.biocompare.com/newsstory.asp?id=335640 Biocompare.com Thu, 29 Jul 2010 05:33:00 GMT